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Abstract Thisstudyisaprospective,randomized,double-
blind study to compare the efﬁcacy and safety of 10 mg/kg
inﬂiximab with those of 3 mg/kg inﬂiximab treatment in
methotrexate-refractory rheumatoid arthritis patients. After
thepatientsreceived3 mg/kginﬂiximabinfusionatweeks0,
2,and6,theywererandomlyassignedtobeadministered3,6
or 10 mg/kg inﬂiximab every 8 weeks from week 14 to 46.
Mean American College of Rheumatology improvement
(ACR-N) at week 54, the primary endpoint, was 51.3% and
58.3% for the 3 mg/kg and 10 mg/kg groups, respectively,
with a statistically signiﬁcant difference. Treatment with
10 mg/kg was found to be remarkably beneﬁcial in patients
who had not responded to three infusions with 3 mg/kg at
week 10. The median changes in the modiﬁed Sharp score
were 0.0 in the two groups. There were no signiﬁcant dif-
ferences in the incidences of adverse events between the
groups. In patients who achieved better clinical response or
greater inhibition of progression of joint damage, trough
serum inﬂiximab level was signiﬁcantly higher than in
patientswhodidnot.Themagnitudesofbothefﬁcacieswere
correlated with the trough serum inﬂiximab level (Clinical-
Trials.gov number: NCT00691028).
Keywords Clinical trial  Inﬂiximab  Rheumatoid
arthritis  Serum level  Tumor necrosis factor
(TNF) antagonist
Introduction
Rheumatoid arthritis (RA) is a chronic, inﬂammatory dis-
ease with the potential to cause substantial joint damage
and disability [1]. Tumor necrosis factor-alpha (TNF-
alpha) plays a central role in the pathogenesis of RA, as
demonstrated by the clinical beneﬁt of anti-TNF alpha
therapy, and inﬂiximab (anti-human TNF-alpha monoclo-
nal antibody) therapy has been a great advance in the
treatment of RA patients [2–7]. The pivotal multinational
clinical study, the Anti-TNF Trial in Rheumatoid Arthritis
with Concomitant Therapy (ATTRACT), showed that
repeated treatment with 3 or 10 mg/kg inﬂiximab was more
effective than methotrexate (MTX) alone in reducing the
clinical symptoms of RA, inhibiting the progression of
joint damage, and improving physical function [3, 8].
However, the main purpose of the ATTRACT study was to
evaluate the usefulness of the concomitant treatment of
inﬂiximab and MTX in comparison with MTX mono-
therapy, and there was not enough evidence to show an
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DOI 10.1007/s10165-009-0195-8advantage for therapy with 10 mg/kg over 3 mg/kg. In this
prospective, randomized, double-blind study (the RISING
study: impact on radiographic and clinical response to
inﬂiximab therapy concomitant with methotrexate in
patients with rheumatoid arthritis by trough serum level in
a dose-escalating study), we examined the usefulness of
inﬂiximab at the maximum dose (10 mg/kg) compared
with the minimum dose (3 mg/kg) as a control. In addition,
we investigated the association between the trough serum
inﬂiximab level and the magnitude of clinical response or
inhibition of progression of joint damage.
Patients and methods
Patients
Eligible patients were those aged between 18 and 75 years
who met the 1987 revised criteria of the American Col-
lege of Rheumatology (ACR) for the classiﬁcation of RA
[9]. Patients were eligible if they had active RA despite
treatment with MTX for more than 12 weeks. Active RA
was deﬁned in this study by the presence of six or more
swollen joints, six or more tender joints, and an erythro-
cyte sedimentation rate (ESR) of at least 28 mm/h, or a
serum C-reactive protein (CRP) concentration of at least
2.0 mg/dl.
Patients were excluded if they had: dysfunction with
Steinbrocker functional class 4 [10]; other connective tis-
sue disease with joint symptoms except Sjo ¨gren’s syn-
drome; a history of inﬂiximab therapy; experience of
therapy with other biological agents within 4 months
before registration; been treated with glucocorticoid
injections or immunosuppressive agents such as lefulno-
mide and tacrolimus. Other exclusion criteria were: a his-
tory of serious or opportunistic infection within 6 months
before registration; active tuberculosis; hepatitis B virus,
hepatitis C virus or human immunodeﬁciency virus (HIV)
carriers; and those with chronic infectious diseases.
Study protocol
The RISING study was a prospective, multicenter, double-
blind, paralleled, comparative study conducted at 88
medical institutes in Japan. The study protocol was
approved by the local institutional review board (IRB) of
each study institution, and was carried out in accordance
with the Helsinki Declaration and Good Clinical Practice.
Patients gave their written informed consent prior to reg-
istration for this study. This study was registered with
http://www.clinicaltrials.gov (NCT00691028).
In the open-label study from weeks 0 to 14, all patients
enrolled in this study received 3 mg/kg inﬂiximab at
weeks 0, 2, and 6. At week 10, patients were randomly
assigned to three treatment groups (3, 6 or 10 mg/kg) using
a dynamic assignment conducted so that the clinical efﬁ-
cacy in ACR20 and ACR50 responses [11] at week 10 was
similar among the three groups. Then, inﬂiximab at doses
of 3, 6 or 10 mg/kg was administered every 8 weeks from
week 14 to 46 in a double-blind fashion, and the efﬁcacies
were evaluated at week 54. Adverse events were evaluated
until week 54. In patients in whom administration was
discontinued, adverse events were assessed until 12 weeks
after ﬁnal administration.
Over the entire study period, disease modifying anti-
rheumatic drugs (other than leﬂunomide, tacrolimus,
cyclosporine, and azathioprine), nonsteroidal anti-inﬂam-
matory drugs, oral glucocorticoids (prednisolone B10 mg/
day), and folic acid preparations were permitted at the
stable dose from at least 4 weeks before registration. The
dose of MTX must have been stable (6 mg/week or more:
the approved maximum dose of MTX for RA in Japan is
8 mg/week) for more than 4 weeks just before registration
and over the entire study period.
Endpoints
The primary endpoint for clinical response was mean
percentage American College of Rheumatology improve-
ment (ACR-N) [4, 12, 13] in 3 and 10 mg/kg groups from
baseline to week 54. ACR responses (ACR20, ACR50, and
ACR70), disease activity score in 28 joints (DAS28)
change [14], and European League against Rheumatism
(EULAR) response [15] were also evaluated at week 54.
We also subanalyzed the clinical response at week 54 in
the patients with EULAR no response to three infusions
(at week 0, 2 and 6) with 3 mg/kg at week 10.
Radiographic progression of joint damage was quanti-
ﬁed as the change from baseline to week 54 in the total
modiﬁed Sharp score (TSS) with a range of 0–390 [16, 17].
Two readers scored the radiographs independently without
knowledge of treatment assignment, clinical response or
the order of the radiographs. Radiographic progression of
disease was deﬁned as damage from baseline in TSS that
was larger than the smallest detectable difference (SDD)
[18]. The SDD in this study was 4.1. The progression of
joint damage was categorized in TSS as follows: pro-
gressed ([4.1),nochange (C-4.1andB4.1),andimproved
(\-4.1).
Improvingphysicalfunctionatweek 54wasevaluatedby
the change in the health assessment questionnaire (HAQ)
score [19] and the percentage of patients who achieved an
improvement of HAQ score exceeding 0.22 units, a value
which may be clinically signiﬁcant [20]. The trough serum
inﬂiximablevelatweek 54wasmeasuredbyenzyme-linked
immunosorbent assay (ELISA), using a monoclonal
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123antibody against inﬂiximab obtained from Centocor Ortho
BiotechInc.,aspreviouslydescribed[2].Thelowestlevelof
inﬂiximabthatcouldbereliablydetectedwas0.1 lg/ml.The
serum trough level was measured in Mitsubishi Tanabe
Pharma Corporation, Osaka, Japan, and the coefﬁcient of
variation or relative error values of intra- and interassay was
within 20% or within ±25%, respectively.
The associations between the clinical response or the
progression of joint damage and the trough serum inﬂix-
imab level at week 54 were investigated in patients for
whom the trough serum levels and DAS28 or TSS were
obtained at week 54.
Statistical analysis
Since the aim of the RISING study is to compare the
usefulness of the 10 mg/kg inﬂiximab treatment with that
of the 3 mg/kg in MTX-refractory RA patients, the sample
size of the study was determined by the predicted values of
ACR-N in 3 and 10 mg/kg groups in the ATTRACT study.
A size of 100 patients per group gave 90% power to detect
a difference in the primary endpoint (ACR-N) between the
3 and 10 mg/kg groups by use of the two-sided t test at
a = 0.05 with detection power of 1 - b = 0.90.
Because the jumped dose escalation from 3 to 10 mg/kg
was thought not to be realistic in clinical practice, we also
investigated the efﬁcacy and safety of 6 mg/kg treatment as
an intermediate dose.
Efﬁcacy was analyzed in the full analysis set. The efﬁ-
cacy other than the joint damage was assessed using the
last observation carried forward approach.
Covariance analysis was performed, using the treatment
groups as factors and ACR-N at week 10 as a covariant, to
compare the parameters for evaluating differences in
clinical responses between the 3 and 10 mg/kg groups. As
a subanalysis, the results were compared between the 3 and
6 mg/kg groups, as well as between the 6 and 10 mg/kg
groups. The HAQ scores were compared by covariance
analysis using the treatment groups as factors and HAQ
score at week 0 as a covariant. To compare the TSS
changes among the treatment groups, we employed Van
Elteren’s test. Spearman’s rank correlation coefﬁcient was
used in assessing the clinical response at week 54 in the
patients with EULAR no response at week 10, and the
association between the efﬁcacy and the trough serum
inﬂiximab level. The incidences of adverse events were
compared using the chi-squared test.
Results
Patient background
In the RISING study, 334 patients were enrolled. Of these,
327 received inﬂiximab therapy at 3 mg/kg during the
open-label period (Fig. 1). At week 10, 314 patients were
randomized. The most common reason for discontinuation
from week 0 to 14 was adverse events. A total of 307
patients were assigned to one of the 3, 6 or 10 mg/kg
groups in the double-blind period starting from week 14.
There were no signiﬁcant differences in the backgrounds of
Fig. 1 Randomization, reason
for discontinuing treatment, and
number of patients completing
the study. All patients received
concomitant methotrexate
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123each group such as age, dose of MTX, disease activity,
progression of joint damage or physical function (Table 1).
Two hundred seventy-two patients (88.6%) of the 307
patients completed this study. The main reason for dis-
continuation was adverse events, and there was no signif-
icant difference among all treatment groups.
Clinical response and improvement in physical function
ACR-N at week 54 in the 10 mg/kg group, the primary
endpoint, was signiﬁcantly higher (p = 0.024) than that in
the 3 mg/kg group (Table 2). The ACR20, ACR50, and
ACR70 responses at week 54 were 75.8%, 60.6%, and
37.4% in the 3 mg/kg group, 78.8%, 58.7%, and 42.3%
in the 6 mg/kg group, and 82.7%, 66.3%, and 43.3% in
the 10 mg/kg group, respectively, with no signiﬁcant
difference. There were signiﬁcant differences in the
reduction in DAS28 change and EULAR responses
between the 3 and 10 mg/kg groups. No signiﬁcant dif-
ference was observed in the proportions of patients
achieving remission (DAS28\2.6) between the two
groups.
Improvement in the HAQ score and the rate of patients
with [0.22 units improvement were more marked in the
10 mg/kg groups than in the 3 mg/kg group, although there
was no signiﬁcant difference.
In the 6 mg/kg group, clinical responses and the
improvement in physical function were intermediate
between the 3 and 10 mg/kg groups.
Figure 2 showed the EULAR responses at week 54 in
patients with EULAR no responses to three infusions with
3 mg/kg at week 10 (n = 37). The rate of responders
Table 1 Baseline demographics and clinical characteristics of patients enrolled in the double-blind study
3 mg/kg
(n = 99)
6 mg/kg
(n = 104)
10 mg/kg
(n = 104)
Age, mean (SD) (years) 49.7 (11.7) 48.8 (11.8) 50.4 (12.5)
Body weight, mean (SD) (kg) 57.3 (11.2) 54.1 (9.1) 54.7 (10.1)
Women, no. (%) 78 (78.8) 86 (82.7) 89 (85.6)
Comorbidity, no. (%) 81 (81.8) 80 (76.9) 78 (75.0)
Steinbrocker grade, no. (%)
I 8 (8.1) 8 (7.7) 14 (13.5)
II 39 (39.4) 44 (42.3) 27 (26.0)
III 30 (30.3) 31 (29.8) 37 (35.6)
IV 22 (22.2) 21 (20.2) 26 (25.0)
Steinbrocker class, no. (%)
1 15 (15.2) 26 (25.0) 15 (14.4)
2 77 (77.8) 68 (65.4) 80 (76.9)
3 7 (7.1) 10 (9.6) 9 (8.7)
Duration of disease, mean (SD), (years) 8.3 (7.8) 7.2 (7.1) 8.4 (7.7)
Duration of disease\3 years, no (%) 26 (26.3) 38 (36.5) 32 (30.8)
Weekly MTX dose, mean (SD) (mg/week) 7.8 (1.6) 7.9 (1.9) 7.7 (1.7)
Oral glucocorticoid, no. (%) 66 (66.7) 73 (70.2) 71 (68.3)
Tender joint count, mean (SD) 18.6 (11.3) 18.0 (10.5) 17.5 (10.9)
Swollen joint count, mean (SD) 14.2 (6.1) 13.1 (8.4) 13.7 (7.3)
CRP level, mean (SD) (mg/dl) 3.0 (2.4) 3.0 (2.7) 3.0 (2.3)
HAQ score, mean (SD) 1.18 (0.64) 1.18 (0.65) 1.21 (0.68)
DAS28, mean (SD) 6.2 (1.0) 6.2 (1.0) 6.2 (0.8)
Total Sharp score, median (IQR) 28.0 (9.0, 77.5)
a 32.2 (12.0, 62.4)
b 38.3 (11.0, 73.8)
Total Sharp score, mean (SD) 49.6 (53.7)
a 47.4 (52.3)
b 51.9 (47.1)
Tender joint count: sixty-eight joints were assessed. Swollen joint count: sixty-six joints were assessed. HAQ score: scores can range from 0 (no
difﬁculty) to 3 (unable to perform this activity). Total Sharp score: scores can range from 0 to 390 (erosion score: 0–230, and joint space
narrowing score: 0–160), with high scores indicating more joint damage
CRP C-reactive protein, HAQ Health Assessment Questionnaire; DAS28 disease activity score in 28 joints; IQR interquartile range
a n = 98
b n = 103
Mod Rheumatol (2009) 19:478–487 481
123(good or moderate response) at week 54 for 3 mg/kg was
only 10%, while it was 56% and 100% for 6 and 10 mg/kg,
respectively, with signiﬁcant differences (p\0.001,
overall).
Radiographic progression
The median changes of TSS at week 54 were 0.0 in the 3
and 10 mg/kg groups (Fig. 3); the progression of joint
damage was inhibited in most of the patients. There were
no signiﬁcant differences between the two groups. In the
6 mg/kg group, the median change in TSS was 0.5, sig-
niﬁcantly different to that at 10 mg/kg group. This was
possibly associated with the ﬁnding that the most rapid
yearly progression of joint damage was in the 6 mg/kg
group. The percentages of patients with no progression of
joint damage (improved or no change) in the 3, 6, and
10 mg/kg groups were 93.0%, 87.0%, and 94.7%, respec-
tively. There was no signiﬁcant difference among these
groups.
Association between trough serum inﬂiximab level
and clinical response or radiographic progression
To explore the usefulness of higher doses of inﬂiximab, the
relationship between trough serum inﬂiximab level and the
magnitude of response was evaluated. The median (inter-
quartile range, IQR) trough serum levels at week 54 in the
3, 6, and 10 mg/kg groups were 0.4 (\0.1, 1.5), 2.3 (0.3,
4.7), and 5.5 (1.5, 9.0) lg/ml, respectively, showing dose
dependency.
As shown in Table 3, a signiﬁcant association was
observed between clinical response and trough serum inf-
liximab levels at week 54. Better EULAR response was
obtained in patients with higher trough serum inﬂiximab
levels (p\0.0001). Furthermore, patients achieving
remission also had signiﬁcantly higher trough serum levels
than patients without remission (p\0.0001).
Signiﬁcant differences were observed among trough
serum inﬂiximab levels at week 54 in patients classiﬁed as
progressed, no change or improved in joint damage
(p = 0.0022). Overall, the proportion of patients showing a
good response increased with increasing trough serum
inﬂiximab level.
On the other hand, we classiﬁed the patients into four
groups based on the trough serum level at week 54 (\0.1,
C0.1 and \1.0, C1.0 and \10, and C10.0 lg/ml), and
examined the EULAR response and the TSS change in
each group (Table 4). Median (IQR) estimated yearly
Table 2 Clinical efﬁcacy of high-dose inﬂiximab therapy in RA patients from baseline to week 54
3 mg/kg
(n = 99)
6 mg/kg
(n = 104)
10 mg/kg
(n = 104)
Reducing signs and symptoms
ACR-N, mean (SD), % 51.3 (32.1) 53.8 (34.4) 58.3 (31.3)*
Reduction in DAS28, mean (SD) 2.30 (1.56) 2.57 (1.69) 2.80 (1.58)**
EULAR response, no. (%)
Moderate or good response 78 (78.8) 87 (83.7) 94 (90.4)**
Good response 37 (37.4) 52 (50.0)* 52 (50.0)*
DAS28 remission (DAS28\2.6), no. (%) 25 (25.3) 34 (32.7) 34 (32.7)
Improving physical function
Improvement in HAQ score, mean (SD) 0.48 (0.70) 0.56 (0.64) 0.59 (0.63)
Rates of clinically meaningful improvement, no. (%) 69 (69.7) 75 (72.1) 76 (73.1)
Clinically meaningful improvement was deﬁned as an improvement in HAQ score[0.22
ACR-N numeric ACR response
*p\0.05 versus 3 mg/kg group, **p\0.01 versus 3 mg/kg group
Fig. 2 Clinical response at week 54 in each group according to
EULAR response criteria in nonresponders at week 10 to three
infusions with 3 mg/kg. *p\0.001, overall
482 Mod Rheumatol (2009) 19:478–487
123progression of TSS before inﬂiximab therapy in each group
(\0.1, C0.1 and \1.0, C0.1 and \1.0, and C10.0 lg/ml)
was 5.7 (3.6, 10.0), 6.7 (2.1, 13.0), 7.2 (3.4, 12.0), and 4.8
(2.6, 7.9), and there was no signiﬁcant difference among
these groups. The proportion of patients assessed as having
no EULAR response decreased with increasing trough
serum level, and there were no patients who showed no
response when the trough serum level was 10.0 lg/ml or
more. Overall, the proportion of patients showing good
response increased with increasing trough serum level.
There was a signiﬁcant correlation between trough serum
level and DAS28 remission as well as EULAR response
(p\0.0001).
Progression of joint damage was most frequently
observed in patients with \0.1 lg/ml trough serum level,
and none of these patients showed improvement. In con-
trast, there was no case with progression of joint damage in
patients with [10.0 lg/ml trough serum level. There was
also a negative correlation between progression of joint
damage and trough serum level (p = 0.0043). The change
of TSS as a cumulative probability plot showed that inhi-
bition of progression of joint damage was more accurately
predicted by an increase in trough serum level (Fig. 4a).
This tendency was more remarkable in early RA patients
whose duration of disease was less than 3 years (Fig. 4b)
[4, 13, 21]. In patients with early RA and with\0.1 lg/ml
trough serum level, the percentage of the progressed
category was 35.0%.
Safety proﬁle
There was no signiﬁcant difference in the incidence of
adverse events or serious adverse events among the groups
(Table 5). The incidences of adverse events leading to
Fig. 3 Progression of joint damage in each group according to total
modiﬁed Sharp score (TSS) at week 54: median (IQR) change score
in TSS (a), and the rate of patients with progression, no change or
improved in TSS (b).
 Radiographic progression was categorized in
TSS as follows: progressed ([4.1), no change (C-4.1 and B4.1), and
improved (\-4.1). W0*: Estimated yearly progression of TSS before
inﬂiximab therapy. W54*: Progression of TSS from baseline to
week 54. **p = 0.022 versus 6 mg/kg group
Table 3 Serum trough level of
inﬂiximab in patients who
showed efﬁcacy of inﬂiximab
Blood samples were obtained at
week 54. Serum inﬂiximab
level were quantiﬁed by ELISA
Radiographic progression was
categorized by total modiﬁed
Sharp score as follows:
progressed ([4.1), no change
(C-4.1 and B4.1), and
improved (\-4.1)
Trough serum inﬂiximab
level, median (IQR), lg/ml
p value (overall)
EULAR response
No response (n = 31) \0.1 (\0.1, 0.3)
Moderate response (n = 106) 1.1 (\0.1, 3.6) \0.0001
Good response (n = 134) 3.0 (1.5, 7.2)
DAS28 remission (DAS28\2.6)
No remission (n = 182) 1.0 (\0.1, 3.7) \0.0001
Remission (n = 89) 3.1 (1.5, 7.1)
Radiographic progression
Progressed (n = 23) 0.5 (\0.1, 2.1)
No change (n = 231) 2.0 (0.1, 5.4) 0.0022
Improved (n = 16) 3.8 (1.6, 6.7)
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123discontinuation or serious infections also showed no sig-
niﬁcant difference. The main adverse events classiﬁed
using the system organ classes (SOCs) were: laboratory
tests (70.2–73.7%), infections and infestations (46.2–
53.8%), and skin and subcutaneous tissue disorders (21.2–
32.3%). The types of adverse events in the groups
administered 6 and 10 mg/kg were similar to those in the
3 mg/kg group (data not shown). No patient died over the
entire study period.
Discussion
Some pivotal clinical studies, such as the ATTRACT
study, have demonstrated that inﬂiximab treatment brought
about a reduction in signs and symptoms, inhibition of the
progression of joint damage, and improvement of physical
function in patients with RA. It was reported that this
treatment was very effective in Japanese RA patients
[7, 22, 23]. However, it has been noted that inﬂiximab is
not sufﬁciently efﬁcacious in some patients because the
approved dosage is only 3 mg/kg every 8 weeks in Japan.
The RISING study was performed to investigate the
efﬁcacy and safety of treatment of RA with inﬂiximab,
comparing 10 mg/kg with 3 mg/kg.
The ACR-N, the primary end point of this study, was
58.3% in the 10 mg/kg group and 51.3% in the 3 mg/kg
group, representing a signiﬁcant difference. In addition, as
regards change in DAS28 and EULAR response criteria,
signiﬁcantlyhigherresponses wereobservedin the 10 mg/kg
Table 4 Magnitude of efﬁcacy in relation to different trough serum inﬂiximab levels
Trough serum inﬂiximab level p value (overall)
\0.1 lg/ml C0.1 and
\1.0 lg/ml
C1.0 and
\10 lg/ml
C10 lg/ml
EULAR response
Total (n = 271) 66 (100) 40 (100) 143 (100) 22 (100)
No response (n = 31) 21 (31.8) 8 (20.0) 2 (1.4) 0 (0.0)
Moderate response (n = 106) 31 (47.0) 20 (50.0) 50 (35.0) 5 (22.7) \0.0001
Good response (n = 134) 14 (21.2) 12 (30.0) 91 (63.6) 17 (77.3)
DAS28 remission
Total (n = 271) 66 (100) 40 (100) 143 (100) 22 (100)
No remission (n = 182) 58 (87.9) 34 (85.0) 80 (55.9) 10 (45.5) \0.0001
Remission (n = 89) 8 (12.1) 6 (15.0) 63 (44.1) 12 (54.5)
Radiographic progression
Total (n = 270) 65 (100) 40 (100) 143 (100) 22 (100)
Progressed (n = 23) 9 (13.8) 4 (10.0) 10 (7.0) 0 (0.0)
No change (n = 231) 56 (86.2) 33 (82.5) 122 (85.3) 20 (90.9) 0.0043
Improved (n = 16) 0 (0.0) 3 (7.5) 11 (7.7) 2 (9.1)
Values are the number (%) of patients
Blood samples were obtained at week 54. Serum inﬂiximab levels were quantiﬁed by ELISA. Patients were grouped according to four different
ranges of trough serum inﬂiximab level as shown
Radiographic progression was categorized in change of total modiﬁed Sharp score as follows: progressed ([4.1), no change (C-4.1 and B4.1),
and improved (\-4.1)
Fig. 4 Cumulative probability
plot of the total modiﬁed Sharp
score (TSS) in relation to trough
serum inﬂiximab level at
week 54 in all patients (a,
n = 270), and in early RA
patients (b, n = 84). Patients
were grouped according to four
different ranges of trough serum
inﬂiximab levels as shown
484 Mod Rheumatol (2009) 19:478–487
123group compared with the 3 mg/kg group. These results are
the ﬁrst evidence of better clinical responses at 10 mg/kg in
comparison with 3 mg/kg in a double-blind study. This was
possibly because we employed the ACR-N and DAS28
change, which indicate the magnitude of improvement,
and the EULAR response, which reﬂects actual disease
activity, whereas the ACR responses, which represent
categorical criteria for improvement, were used in the
ATTRACT study. In addition, when we focused on non-
responders at 10 weeks, EULAR response rates at week 54
were signiﬁcantly increased in the high-dose groups com-
pared with those in 3 mg/kg group.
The ATTRACT trial and the Safety Trial for Rheuma-
toid Arthritis with Remicade (inﬂiximab) Therapy
(START) have already demonstrated a signiﬁcant associ-
ation between clinical response and trough serum inﬂix-
imab level [24, 25]. In the RISING study, a signiﬁcant
correlation was observed between serum trough level and
EULAR response or DAS28 remission. The median trough
serum level at week 54 in EULAR nonresponders was
\0.1 lg/ml, and that in EULAR responders (good or
moderate response) was 1.1 lg/ml, which was consistent
with that reported in the ATTRACT and START studies.
This suggests that a trough serum level of 1.0 lg/ml is
the threshold level for clinical response, as reported
previously.
Inﬂiximab treatment inhibited the progression of joint
damage in most of patients regardless of inﬂiximab dose in
the RISING study. It is interesting to note that inﬂiximab
inhibited progression of joint damage even in patients
receiving low dose of MTX. A signiﬁcant correlation
between progression or improvement of joint damage and
trough serum inﬂiximab level, which had not been
investigated sufﬁciently so far, was also shown, raising the
possibility that joint damage might progress in patients
with a low trough serum level. This correlation was more
remarkable in early RA patients in whom joint destruction
progresses rapidly. The factors that inﬂuenced the trough
serum inﬂiximab level were thought to be the serum
clearance of inﬂiximab as well as production of anti-inf-
liximab antibodies [26]. This study showed the signiﬁcant
association between serum trough level and clinical
responses or radiographic progression. It appears that anti-
inﬂiximab antibodies may be one of the important factors
that inﬂuence the efﬁcacies of inﬂiximab therapy.
In the RISING study, the safety proﬁle of the high-dose
groups was similar to that of the 3 mg/kg group, and no
signiﬁcant difference was found in the incidence of adverse
events or serious adverse events including infections.
However, the START study showed that the incidence of
serious infections in the 10 mg/kg group increased in the
22-week period after the start of treatment [5]. It was
reported that bacterial pneumonia (a major serious infec-
tion) was commonly observed in the early phase of the
treatment (until week 14) in the Japanese post-marketing
surveillance (PMS) of 5,000 patients [27]. It should be
noted that the three induction infusions at 0, 2, and 6 weeks
in the RISING study used a 3 mg/kg dose for all three
dosing groups, whereas in the previous reports the same
dose was used throughout the entire study period, including
the induction phase. The different dose in the induction
phases of these studies might account for the different
results regarding serious adverse events. It is very impor-
tant to examine the association between trough serum
inﬂiximab level and safety. However, the time of occur-
rence of adverse events varied in every patient, and we did
Table 5 Incidence of adverse events (AEs)
All periods
(0–54 weeks)
Open-label
period
(0–14 weeks)
Double-blind period
(14–54 weeks)
3 mg/kg 6 mg/kg 10 mg/kg
(n = 327) (n = 327) (n = 99) (n = 104) (n = 104)
Any AEs 319 (97.6) 242 (74.0) 97 (98.0) 97 (93.3) 101 (97.1)
Serious AEs
a 38 (11.6) 17 (5.2) 7 (7.1) 5 (4.8) 9 (8.7)
AEs leading to discontinuation of study agents 39 (11.9) 19 (5.8) 7 (7.1) 9 (8.7) 5 (4.8)
Infections 230 (70.3) 124 (37.9) 56 (56.6) 57 (54.8) 67 (64.4)
Serious infections 17 (5.2) 7 (2.1) 3 (3.0) 2 (1.9) 5 (4.8)
Infections leading to discontinuation of study agents 12 (3.7) 6 (1.8) 3 (3.0) 3 (2.9) 0 (0.0)
Infusion reactions
b 92 (28.1) 41 (12.5) 17 (17.2) 25 (24.0) 23 (22.1)
Serious infusion reactions 1 (0.3) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Values are the number (%) of patients
a Any AEs that resulted in any life-threatening events, inpatient hospitalizations, prolongation of existing hospitalization or signiﬁcant disability/
incapacity
b Any AEs that occurred during an infusion or within 2 h after completion of an infusion
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123not measure the serum level at week 54 in patients who
discontinued inﬂiximab treatment because of adverse
events. Therefore, we were unable to investigate the
association between them. If there is a signiﬁcant associ-
ation between inﬂiximab serum level and safety, the efﬁ-
cacy should be higher in the discontinued patients than in
the patients who continued with inﬂiximab therapy because
the efﬁcacy is dependent on the inﬂiximab level. However,
the ACR-N in the discontinued patients before discontin-
uation was lower than that of the continued patients at
week 54. This means that the serum inﬂiximab level of the
former patients was lower than that of the latter. Further-
more, no signiﬁcant difference of the rate of adverse events
or infections was observed between the 3, 6, and 10 mg/kg
groups in this study. These results may indicate the pos-
sibility that serum trough inﬂiximab level does not inﬂu-
ence the safety of inﬂiximab therapy. Further investigation
on this matter is considered to be necessary.
The RISING study showed that inﬂiximab treatment
with 3 mg/kg resulted in a good clinical response in many
patients, while treatment with 10 mg/kg demonstrated a
statistically signiﬁcant advantage compared with 3 mg/kg
in the efﬁcacy outcomes. What is noted in this study was
that inﬂiximab treatment with 10 mg/kg was found bene-
ﬁcial in those patients who had not responded to three
infusions of inﬂiximab with 3 mg/kg at week 10. It is
clinically relevant to escalate the dose of inﬂiximab when
patients do not respond to 3 mg/kg.
It was also suggested that higher trough serum inﬂix-
imab levels by dose escalation of inﬂiximab provided
better clinical responses and greater inhibition of progres-
sion of joint damage.
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